Loading stock data…
RARE
$24.77+0.08 (+0.32%)
Market ClosedLast close May 1
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ultragenyx Pharmaceutical Inc. in the Healthcare sector is trading at $24.77. The stock is currently 42% below its 52-week high of $42.37, remaining 10.6% below its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why RARE maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.77
Potential Upside
5%
Whystock Fair Value$26.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$53.35+115.4%
Range$25.00 – $84.00
Fundamentals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, E...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
666.16%
Volume
Today's trading volume
1.41M
Recent News
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 10 best biotech stocks with highest upside potential. On April 16, Morgan Stanley increased the price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from $50 to $67, resulting in an adjusted upside potential in excess of 178% at the prevailing level. The firm also reiterated its Outperform rating […]
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Accepts Ultragenyx (RARE) BLA for Sanfilippo Syndrome Gene Therapy UX111
Ultragenyx (NASDAQ:RARE) is one of the 10 Overlooked Growth Stocks to Buy Now. Ultragenyx (NASDAQ:RARE) is one of the overlooked growth stocks to buy now. On April 2, Ultragenyx announced that the US FDA accepted the resubmitted BLA for UX111, an investigational AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA). The FDA set a […]
Is Ultragenyx Pharmaceutical (RARE) Pricing Reflect Its Long Term Potential After 5 Year Slump
If you are wondering whether Ultragenyx Pharmaceutical's current share price reflects its true worth, this breakdown will help you separate story from numbers. The stock last closed at US$23.91, with returns of 6.5% over 7 days, 4.7% over 30 days and 1.3% year to date, against a 27.9% decline over the past year and a 78.2% decline over 5 years. Recent attention on Ultragenyx Pharmaceutical has focused on its position within the biotech space and how investors are weighing the risks and...